Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Polyethlyene Glycol 200 can Protect Rats against Drug-Induced Kidney Toxicity through Inhibition of the Renal Organic Anion Transporter 3.

Gu YZ, Chu X, Houle R, Vlasakova K, Koeplinger KA, Bourgeois I, Palyada K, Anderson KD, Brynczka C, Bhatt B, Chen F, Smith R, Amin R, Glaab WE, Lebron J, Cox K, Sistare FD.

Toxicol Sci. 2019 Aug 12. pii: kfz186. doi: 10.1093/toxsci/kfz186. [Epub ahead of print]

PMID:
31406999
2.

Role of transporters in the disposition of a novel β-lactamase inhibitor: relebactam (MK-7655).

Chan G, Houle R, Lin M, Yabut J, Cox K, Wu J, Chu X.

J Antimicrob Chemother. 2019 Jul 1;74(7):1894-1903. doi: 10.1093/jac/dkz101.

PMID:
30891606
3.

In Vitro Evaluation of the Drug Interaction Potential of Doravirine.

Bleasby K, Fillgrove KL, Houle R, Lu B, Palamanda J, Newton DJ, Lin M, Chan GH, Sanchez RI.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e02492-18. doi: 10.1128/AAC.02492-18. Print 2019 Apr.

4.

Structure-Activity Relationship of Novel and Selective Biaryl-Chroman GPR40 AgoPAMs.

Chen HY, Plummer CW, Xiao D, Chobanian HR, DeMong D, Miller M, Trujillo ME, Kirkland M, Kosinski D, Mane J, Pachanski M, Cheewatrakoolpong B, Di Salvo J, Thomas-Fowlkes B, Souza S, Tatosian DA, Chen Q, Hafey MJ, Houle R, Nolting AF, Orr R, Ehrhart J, Weinglass AB, Tschirret-Guth R, Howard AD, Colletti SL.

ACS Med Chem Lett. 2018 Jun 14;9(7):685-690. doi: 10.1021/acsmedchemlett.8b00149. eCollection 2018 Jul 12.

5.

A Tandem Cycling Program: Feasibility and Physical Performance Outcomes in People With Parkinson Disease.

McGough EL, Robinson CA, Nelson MD, Houle R, Fraser G, Handley L, Jones ER, Amtmann D, Kelly VE.

J Neurol Phys Ther. 2016 Oct;40(4):223-9. doi: 10.1097/NPT.0000000000000146.

PMID:
27576091
6.

Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin.

Prueksaritanont T, Chu X, Evers R, Klopfer SO, Caro L, Kothare PA, Dempsey C, Rasmussen S, Houle R, Chan G, Cai X, Valesky R, Fraser IP, Stoch SA.

Br J Clin Pharmacol. 2014 Sep;78(3):587-98. doi: 10.1111/bcp.12377.

7.

Raltegravir has a low propensity to cause clinical drug interactions through inhibition of major drug transporters: an in vitro evaluation.

Rizk ML, Houle R, Chan GH, Hafey M, Rhee EG, Chu X.

Antimicrob Agents Chemother. 2014;58(3):1294-301. doi: 10.1128/AAC.02049-13. Epub 2013 Dec 2.

8.

Design and synthesis of potent, isoxazole-containing renin inhibitors.

Fournier PA, Arbour M, Cauchon E, Chen A, Chefson A, Ducharme Y, Falgueyret JP, Gagné S, Grimm E, Han Y, Houle R, Lacombe P, Lévesque JF, MacDonald D, Mackay B, McKay D, Percival MD, Ramtohul Y, St-Jacques R, Toulmond S.

Bioorg Med Chem Lett. 2012 Apr 15;22(8):2670-4. doi: 10.1016/j.bmcl.2012.03.014. Epub 2012 Mar 11.

PMID:
22450130
9.

Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of spirocyclic piperidines.

Chen A, Aspiotis R, Campeau LC, Cauchon E, Chefson A, Ducharme Y, Falgueyret JP, Gagné S, Han Y, Houle R, Laliberté S, Larouche G, Lévesque JF, McKay D, Percival D.

Bioorg Med Chem Lett. 2011 Dec 15;21(24):7399-404. doi: 10.1016/j.bmcl.2011.10.013. Epub 2011 Oct 19.

PMID:
22071301
10.

Impact of passive permeability and gut efflux transport on the oral bioavailability of novel series of piperidine-based renin inhibitors in rodents.

Lévesque JF, Bleasby K, Chefson A, Chen A, Dubé D, Ducharme Y, Fournier PA, Gagné S, Gallant M, Grimm E, Hafey M, Han Y, Houle R, Lacombe P, Laliberté S, MacDonald D, Mackay B, Papp R, Tschirret-Guth R.

Bioorg Med Chem Lett. 2011 Sep 15;21(18):5547-51. doi: 10.1016/j.bmcl.2011.06.095. Epub 2011 Jun 28.

PMID:
21784634
11.

Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of tertiary alcohol-bearing piperidines.

Chen A, Cauchon E, Chefson A, Dolman S, Ducharme Y, Dubé D, Falgueyret JP, Fournier PA, Gagné S, Gallant M, Grimm E, Han Y, Houle R, Huang JQ, Hughes G, Jûteau H, Lacombe P, Lauzon S, Lévesque JF, Liu S, Macdonald D, Mackay B, McKay D, Percival MD, St-Jacques R, Toulmond S.

Bioorg Med Chem Lett. 2011 Jul 1;21(13):3976-81. doi: 10.1016/j.bmcl.2011.05.014. Epub 2011 May 14.

PMID:
21641209
12.

Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of pyridone-substituted piperidines.

Chen A, Campeau LC, Cauchon E, Chefson A, Ducharme Y, Dubé D, Falgueyret JP, Fournier PA, Gagné S, Grimm E, Han Y, Houle R, Huang JQ, Lacombe P, Laliberté S, Lévesque JF, Liu S, MacDonald D, Mackay B, McKay D, Percival MD, Regan C, Regan H, St-Jacques R, Toulmond S.

Bioorg Med Chem Lett. 2011 Jul 1;21(13):3970-5. doi: 10.1016/j.bmcl.2011.05.013. Epub 2011 May 14.

PMID:
21621998
13.

New indole amide derivatives as potent CRTH2 receptor antagonists.

Zaghdane H, Boyd M, Colucci J, Simard D, Berthelette C, Leblanc Y, Wang Z, Houle R, Lévesque JF, Molinaro C, Hamel M, Stocco R, Sawyer N, Sillaots S, Gervais F, Gallant M.

Bioorg Med Chem Lett. 2011 Jun 1;21(11):3471-4. doi: 10.1016/j.bmcl.2011.03.085. Epub 2011 Mar 30.

PMID:
21515053
14.

The discovery and synthesis of potent zwitterionic inhibitors of renin.

Aspiotis R, Chen A, Cauchon E, Dubé D, Falgueyret JP, Gagné S, Gallant M, Grimm EL, Houle R, Juteau H, Lacombe P, Laliberté S, Lévesque JF, MacDonald D, McKay D, Percival MD, Roy P, Soisson SM, Wu T.

Bioorg Med Chem Lett. 2011 Apr 15;21(8):2430-6. doi: 10.1016/j.bmcl.2011.02.067. Epub 2011 Feb 18.

PMID:
21429746
15.

Azaindoles as potent CRTH2 receptor antagonists.

Simard D, Leblanc Y, Berthelette C, Zaghdane MH, Molinaro C, Wang Z, Gallant M, Lau S, Thao T, Hamel M, Stocco R, Sawyer N, Sillaots S, Gervais F, Houle R, Lévesque JF.

Bioorg Med Chem Lett. 2011 Jan 15;21(2):841-5. doi: 10.1016/j.bmcl.2010.11.084. Epub 2010 Nov 21.

PMID:
21185722
16.

Discovery of MK-7246, a selective CRTH2 antagonist for the treatment of respiratory diseases.

Gallant M, Beaulieu C, Berthelette C, Colucci J, Crackower MA, Dalton C, Denis D, Ducharme Y, Friesen RW, Guay D, Gervais FG, Hamel M, Houle R, Krawczyk CM, Kosjek B, Lau S, Leblanc Y, Lee EE, Levesque JF, Mellon C, Molinaro C, Mullet W, O'Neill GP, O'Shea P, Sawyer N, Sillaots S, Simard D, Slipetz D, Stocco R, Sørensen D, Truong VL, Wong E, Wu J, Zaghdane H, Wang Z.

Bioorg Med Chem Lett. 2011 Jan 1;21(1):288-93. doi: 10.1016/j.bmcl.2010.11.015. Epub 2010 Nov 5.

PMID:
21106375
17.

Addressing time-dependent CYP 3A4 inhibition observed in a novel series of substituted amino propanamide renin inhibitors, a case study.

Chen A, Dubé D, Dubé L, Gagné S, Gallant M, Gaudreault M, Grimm E, Houle R, Lacombe P, Laliberté S, Liu S, MacDonald D, Mackay B, Martin D, McKay D, Powell D, Lévesque JF.

Bioorg Med Chem Lett. 2010 Sep 1;20(17):5074-9. doi: 10.1016/j.bmcl.2010.07.030. Epub 2010 Jul 11.

PMID:
20673718
18.

Design and optimization of a substituted amino propanamide series of renin inhibitors for the treatment of hypertension.

Chen A, Bayly C, Bezençon O, Richard-Bildstein S, Dubé D, Dubé L, Gagné S, Gallant M, Gaudreault M, Grimm E, Houle R, Lacombe P, Laliberté S, Lévesque JF, Liu S, MacDonald D, Mackay B, Martin D, McKay D, Powell D, Remen L, Soisson S, Toulmond S.

Bioorg Med Chem Lett. 2010 Apr 1;20(7):2204-9. doi: 10.1016/j.bmcl.2010.02.036. Epub 2010 Feb 18.

PMID:
20206513
19.

Primary cultures of human hepatocytes isolated from hepatitis C virus-infected cirrhotic livers as a model to study hepatitis C infection.

Raymond VA, Selliah S, Ethier C, Houle R, Jouan L, Maniere T, Lamarre D, Willems B, Bilodeau M.

Liver Int. 2009 Jul;29(6):942-9. doi: 10.1111/j.1478-3231.2009.01996.x. Epub 2009 Mar 3.

PMID:
19302183
20.

The identification of potent, selective, and bioavailable cathepsin S inhibitors.

Gauthier JY, Black WC, Courchesne I, Cromlish W, Desmarais S, Houle R, Lamontagne S, Li CS, Massé F, McKay DJ, Ouellet M, Robichaud J, Truchon JF, Truong VL, Wang Q, Percival MD.

Bioorg Med Chem Lett. 2007 Sep 1;17(17):4929-33. Epub 2007 Jun 10.

PMID:
17590332
21.

Use of a benzyloxy-substituted lactone cyclooxygenase-2 inhibitor as a selective fluorescent probe for CYP3A activity in primary cultured rat and human hepatocytes.

Nicoll-Griffith DA, Chauret N, Houle R, Day SH, D'Antoni M, Silva JM.

Drug Metab Dispos. 2004 Dec;32(12):1509-15.

PMID:
15550722
22.
23.

Antiapoptotic effect of EGF on mouse hepatocytes associated with downregulation of proapoptotic Bid protein.

Ethier C, Raymond VA, Musallam L, Houle R, Bilodeau M.

Am J Physiol Gastrointest Liver Physiol. 2003 Aug;285(2):G298-308. Epub 2003 Apr 17.

24.

Retention of transporter activities in cryopreserved, isolated rat hepatocytes.

Houle R, Raoul J, Lévesque JF, Pang KS, Nicoll-Griffith DA, Silva JM.

Drug Metab Dispos. 2003 Apr;31(4):447-51.

PMID:
12642471
25.

Evaluation of human hepatocyte incubation as a new tool for metabolism study of androstenedione and norandrostenedione in a doping control perspective.

Lévesque JF, Gaudreault M, Houle R, Chauret N.

J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Nov 15;780(1):145-53. Erratum in: J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Apr 25;787(2):427.

PMID:
12383490
26.

[Factors influencing changes in the knowledge of Catalan in Spanish Catalonia].

Houle R.

Cah Que Demogr. 1997 Autumn;26(2):277-305; 341. French.

PMID:
12348494
27.

Hepatic artery buffer response following left portal vein ligation: its role in liver tissue homeostasis.

Rocheleau B, Ethier C, Houle R, Huet PM, Bilodeau M.

Am J Physiol. 1999 Nov;277(5):G1000-7. doi: 10.1152/ajpgi.1999.277.5.G1000.

PMID:
10564106
28.

Evaluation of hepatocyte injury following partial ligation of the left portal vein.

Bilodeau M, Aubry MC, Houle R, Burnes PN, Ethier C.

J Hepatol. 1999 Jan;30(1):29-37.

PMID:
9927148
29.
30.

The IV in readiness--a mixed blessing?

Saucier JR, Klippel AP, Houle R.

JACEP. 1978 Jul;7(7):289. No abstract available.

PMID:
671944
31.

Zinc chloride keratopathy and cataracts.

Houle RE, Grant WM.

Am J Ophthalmol. 1973 Jun;75(6):992-6. No abstract available.

PMID:
4708638
32.

Device for positioning the lower extremity.

Kellor S, Houle RJ.

Arch Phys Med Rehabil. 1971 May;52(5):235-6. No abstract available.

PMID:
5581036
33.

Evaluation of seat devices designed to prevent ischemic ulcers in paraplegic patients.

Houle RJ.

Arch Phys Med Rehabil. 1969 Oct;50(10):587-94. No abstract available.

PMID:
5351692
34.

Alcohol, vasopressin, and intraocular pressure.

Houle RE, Grant WM.

Invest Ophthalmol. 1967 Apr;6(2):145-54. No abstract available.

PMID:
6022594
35.

Spur-shaped phalangeal exostosis. A case report.

Houle RJ.

J Am Podiatry Assoc. 1967 Jan;57(1):21. No abstract available.

PMID:
6035632
36.

Influence of norethynodrel with mestranol on intraocular pressure in glaucoma. II. A controlled double-blind study.

Meyer EJ, Roberts CR, Leibowitz HM, McGowan B, Houle RE.

Arch Ophthalmol. 1966 Jun;75(6):771-3. No abstract available.

PMID:
5327793
37.

Cutis hyperelastica. A case report.

Houle RJ.

J Am Podiatry Assoc. 1965 Oct;55(10):716. No abstract available.

PMID:
5828238

Supplemental Content

Support Center